Thureau S, Mallet R, Gouel P, Modzelewski R, Vera P
Département de radiothérapie et de physique médicale, centre Henri-Becquerel, Rouen, France; Unité QuantIF LITIS EA 4108, université de Rouen, Normandie, France; Département d'imagerie, centre Henri-Becquerel, Rouen, France.
Département de radiothérapie et de physique médicale, centre Henri-Becquerel, Rouen, France.
Cancer Radiother. 2022 Oct;26(6-7):890-893. doi: 10.1016/j.canrad.2022.07.004. Epub 2022 Sep 6.
Despite significant therapeutic advances in the treatment of locally advanced inoperable non-small cell lung cancer (NSCLC), notably through adjuvant immunotherapy, the rate of therapeutic failure remains high. The use of positron emission tomography with fluorodeoxyglucose (FDG-PET), respiratory motion and intensity modulated radiotherapy (IMRT) have led to therapeutic improvements with reduced toxicity and better local control. The optimal dose to be delivered remains unknown due to discordant results of studies for almost 20 years and the way to define the area to benefit from a dose increase (whole volume, subvolume defined by pre- or per-radiotherapy PET).
尽管在局部晚期不可切除非小细胞肺癌（NSCLC）的治疗方面取得了重大治疗进展，尤其是通过辅助免疫疗法，但治疗失败率仍然很高。使用氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）、呼吸运动和调强放疗（IMRT）已带来了治疗改善，毒性降低且局部控制更好。由于近20年的研究结果不一致，以及确定从剂量增加中获益区域的方式（全容积、放疗前或放疗期间PET定义的子容积），有待给予的最佳剂量仍然未知。
